Special Issue: Biotechnology Bootcamp Editorial Vol.18 No. 2 (2012) Editorial: The Biotechnology Entrepreneurship Boot Camp: From Lectern to Printing Press Stephen M Sammut This issue of the Journal of Commercial Biotechnology focuses on the proceedings of the Seventh Annual Biotechnology Entrepreneurship Boot Camp held in conjunction with the Biotechnology Commentary Vol.18 No. 2 (2012) New paradigms in drug R&D: A personal perspective David C U'Prichard The Author discusses the recent productivity problems in the pharmaceutical industry, in the context of his 30 year career, and the current responses of the industry driven strongly by disag Special Section Vol.18 No. 2 (2012) Project, Product or Company Arthur Boni This article focuses on the essentials of building effective, collaborative, team-based organizations. The entrepreneurs and innovators who found and build technology-based organizations Special Section Vol.18 No. 2 (2012) The Basics of Coverage, Coding, and Reimbursement Robert Wanerman The process of commercializing a new item or service in the U.S. health care market involves three distinct but necessary components: coverage, coding, and reimbursement. This article pr Special Section Vol.18 No. 2 (2012) Transition from the Lab to the Clinic James G Kenimer Before considering the specific regulatory requirements and expectations relating to your product it is informative to understand who regulates and why. Special Section Vol.18 No. 2 (2012) Building Teams in Entrepreneurial Companies Arthur Boni This article focuses on the essentials of building effective, collaborative, team-based organizations. The entrepreneurs and innovators who found and build technology-based organizations Special Section Vol.18 No. 2 (2012) The Pitch to Investors and Partners Arthur Boni This article covers the essentials of constructing and delivering a “pitch†of a business opportunity to potential investors or corporate partners. We advocate constructin Special Section Vol.18 No. 2 (2012) Strategic Engagement of the Science-Business Media Moira A. Gunn As surely as the bio-enterprise can benefit from positive media coverage, it cannot thrive in the face of unanswered negative and/or inaccurate media attention. On all counts, the bio-ent Special Section Vol.18 No. 2 (2012) Achieving optimal financial and strategic transaction outcomes for small to mid-sized privately funded start-ups Benjamin P Chen Special Section Vol.18 No. 2 (2012) Partnering With the NIH: Now Part of the “Value Proposition†for Start-ups Steve Ferguson For many years the United States has led the world in government support for non-military research and development (R&D), especially support for work that directly relates to health a Special Section Vol.18 No. 2 (2012) Licensing, Partnering, Strategic Alliances and University Relationships Wesley Daniel Blakeslee Abstract The biopharmaceutical industry has been undergoing change for a number of years and that change is accelerating. Larger pharmaceutical companies are acquirin Special Section Vol.18 No. 2 (2012) What Every Biotech Entrepreneur Needs to Know about VC Due Diligence Stephen M Sammut Due diligence, as it applies to venture capital, is actually imprecise. Origins of the term are based in banking case law. Due diligence to the attorney is more of a precise concept. A be Special Section Vol.18 No. 2 (2012) Valuation Methods in Early-Stage Biotechnology Enterprises: The “Venture Capital Method†at Work Stephen M. Sammut Valuation approaches to biotechnology companies by angel investors and venture capitalists often appear to the entrepreneurs to be based on voodoo rather than sound principles of finance. Wh Special Section Vol.18 No. 2 (2012) The Art of the Cap Table Ashley John Stevens This article provides an overview of the impact of raising capital on the equity ownership structure of a biotechnology company. The equity ownership structure as captured in a table of capi